Table 2.
Survival analysis of the clinicopathologic factors in LND group before and after PSM matching
| Characteristics | 10 years | 10 years | ||
|---|---|---|---|---|
| Before PSM (n = 2652) | P value | After PSM (n = 2048) | P value | |
| Age, years | < 0.001 | < 0.001 | ||
| ≤ 60 | 90.3 ± 1.2 | 90.7 ± 1.3 | ||
| > 60 | 65.5 ± 2.3 | 69.1 ± 2.8 | ||
| Sex | 0.610 | 0.800 | ||
| Male | 78.0 ± 1.8 | 82.9 ± 1.9 | ||
| Female | 80.4 ± 1.7 | 81.5 ± 1.9 | ||
| Race | 0.651 | 0.727 | ||
| White | 79.1 ± 1.3 | 82.1 ± 1.5 | ||
| Black | 78.8 ± 4.6 | 82.9 ± 3.5 | ||
| Others | 74.7 ± 10.5 | 82.3 ± 10.3 | ||
| Unknown | - | |||
| Primary location | 0.023 | 0.989 | ||
| Jejunum | 66.8 ± 6.2 | 82.2 ± 1.4 | ||
| Ileum | 80.1 ± 1.3 | 80.7 ± 7.1 | ||
| Tumor size, cm | < 0.001 | < 0.001 | ||
| ≤ 1 | 85.2 ± 2.1 | 90.0 ± 2.0 | ||
| 1–5 | 77.3 ± 1.6 | 79.8 ± 1.7 | ||
| > 5 | 62.9 ± 10.1 | 65.6 ± 9.8 | ||
| Histologic typea | 0.249 | 0.071 | ||
| 8240 | 79.3 ± 1.4 | 83.1 ± 1.4 | ||
| 8246 | 78.5 ± 3.4 | 78.1 ± 4.0 | ||
| 8249 | 75.2 ± 12.6 | 65.5 ± 16.4 | ||
| Surgery | 0.806 | 0.429 | ||
| Simple resection | 78.0 ± 1.7 | 83.0 ± 1.7 | ||
| Partial resection | 81.6 ± 2.3 | 82.1 ± 2.5 | ||
| Total resection | 79.9 ± 3.5 | 78.9 ± 3.9 | ||
| Tumor differentiation | 0.102 | 0.040 | ||
| Well | 80.7 ± 2.1 | 85.0 ± 1.9 | ||
| Moderate | 77.5 ± 3.6 | 75.6 ± 4.4 | ||
| Poor | 58.3 ± 16.8 | 45.5 ± 32.4 | ||
| Undifferentiated | - | |||
| Unknown | 78..4 ± 1.8 | 80.9 ± 2.1 | ||
| AJCC T status | < 0.001 | < 0.001 | ||
| T1 | 88.4 ± 2.8 | 88.4 ± 2.8 | ||
| T2 | 87.0 ± 2.3 | 87.0 ± 2.3 | ||
| T3 | 79.8± 2.4 | 79.8± 2.4 | ||
| T4 | 75.3 ± 3.1 | 74.6 ± 3.6 | ||
| N stage | 0.441 | 0.481 | ||
| N0 | 77.7 ± 2.6 | 80.5 ± 3.0 | ||
| N1 | 79.3 ± 1.5 | 82.5 ± 1.5 | ||
| N2 | 86.3 ± 6.6 | 86.9 ± 7.0 | ||
| TNM stage | 0.701 | 0.654 | ||
| I | 84.9 ± 42.1 | 86.8 ± 4.1 | ||
| II | 74.7 ± 2.3 | 78.5 ± 4.3 | ||
| III | 79.3 ± 1. 4 | 82.3 ± 1. 5 | ||
| ELNs | < 0.001 | 0.003 | ||
| 1–14 | 75.8 ± 1.7 | 80.0 ± 1.9 | ||
| ≥ 15 | 84.6 ± 1.8 | 84.1 ± 1.9 | ||
| NLNs | < 0.001 | 0.004 | ||
| 1–9 | 75.3 ± 1.8 | 75.2 ± 1.9 | ||
| ≥ 10 | 83.2 ± 1.8 | 84.4 ± 1.7 |
AJCC American Joint Committee on Cancer, TNM tumor-node-metastasis, ELNs examined lymph nodes,NLN snegative examined lymph nodes
aInternational Classification of Diseases for Oncology, 3rd Edition (ICD-O-3): 8240, Carcinoid tumor; 8246, Carcinoid carcinoma; 8249, Atypical carcinoid tumor